Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for Miles D. White
46.50
-0.03 (-0.06%)
Mar 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 46.10 - 46.79
52 week 36.65 - 47.88
Open 46.41
Vol / Avg. 4.37M/5.42M
Mkt cap 70.21B
P/E 41.13
Div/yield 0.24/2.06
EPS 1.13
Shares 1.51B
Beta 0.38
Inst. own 70%
Apr 24, 2015
Abbott Laboratories Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 14, 2015
Q1 2015 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 3, 2015
Abbott Laboratories at Cowen Health Care Conference
Feb 12, 2015
Abbott Laboratories at Leerink Global Healthcare Conference
Jan 29, 2015
Q4 2014 Abbott Laboratories Earnings Release
Jan 29, 2015
Q4 2014 Abbott Laboratories Earnings Call - Webcast
Jan 12, 2015
Abbott Laboratories at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 11.95% 8.50%
Operating margin 15.29% 12.75%
EBITD margin - 21.29%
Return on average assets 6.05% 4.09%
Return on average equity 11.42% 7.37%
Employees 77,000 -
CDP Score - 93 B

Address

100 Abbott Park Rd
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company�s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines; diagnostic products, which include a range of diagnostic systems and tests; nutritional products, which include a range of pediatric and adult nutritional products, and vascular products, which include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company is also engaged in the field of electrophysiology with technologies that can transform how physicians treat people with complex heart rhythm disorders.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 50
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 53
Bio & Compensation  - Reuters
John C. Landgraf Executive Vice President, Nutritional Products.
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Heather L. Mason Executive Vice President, Nutritional Products, Global Commercial Operations.
Age: 54
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 52
Bio & Compensation  - Reuters